arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

FATE THERAPEUTICS INC

FATE
$2.80 ▲ +0.31 (+12.45%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
60 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

FATE THERAPEUTICS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $336.1M
Dividend Yield
Revenue Growth -20.3%
Op. Margin None
ROIC -14.5%
FCF / Share $-0.26
Trailing P/E
Price / Book 1.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

60-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.30M
↓ -20.3%
Net Income Profit after all expenses
$-31.21M
↑ +17.0%
Operating Margin Operating profit as % of sales
-48.5%
↑ +66.6%
FCF / Share Free cash flow per share
$-0.26
↑ +12.5%
Long-Term Debt Long-term obligations
$10.96M
↓ -14.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 60 quarters